Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
Drug-induced cardiotoxicity (DICT) is an important concern of drug safety in both drug development and clinical application. The clinical manifestations of DICT include cardiomyopathy, arrhythmia, myocardial ischemia, heart failure, and a series of cardiac structural and functional changes. The occu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.966261/full |
| _version_ | 1798020569632866304 |
|---|---|
| author | Mo-Yun Li Mo-Yun Li Li-Ming Peng Li-Ming Peng Li-Ming Peng Xiao-Ping Chen Xiao-Ping Chen Xiao-Ping Chen |
| author_facet | Mo-Yun Li Mo-Yun Li Li-Ming Peng Li-Ming Peng Li-Ming Peng Xiao-Ping Chen Xiao-Ping Chen Xiao-Ping Chen |
| author_sort | Mo-Yun Li |
| collection | DOAJ |
| description | Drug-induced cardiotoxicity (DICT) is an important concern of drug safety in both drug development and clinical application. The clinical manifestations of DICT include cardiomyopathy, arrhythmia, myocardial ischemia, heart failure, and a series of cardiac structural and functional changes. The occurrence of DICT has negative impacts on the life quality of the patients, brings additional social and economic burden. It is important to identify the potential factors and explore the mechanisms of DICT. Traditional cardiovascular risk factors can only partially explain the risk of DICT. Pharmacogenomic studies show accumulated evidence of genetics in DICT and suggest the potential to guide precision therapy to reduce risk of cardiotoxicity. The comprehensive application of technologies such as third-generation sequencing, human induced pluripotent stem (iPS) cells and genome editing has promoted the in-depth understanding of the functional role of susceptible genes in DICT. This paper reviewed drugs that cause DICT, the clinical manifestations and laboratory tests, as well as the related content of genetic variations associated with the risk of DICT, and further discussed the implication of new technologies in pharmacogenomics of DICT. |
| first_indexed | 2024-04-11T16:59:41Z |
| format | Article |
| id | doaj.art-f74432c315d3436484787947646d2609 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T16:59:41Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-f74432c315d3436484787947646d26092022-12-22T04:13:12ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-10-01910.3389/fcvm.2022.966261966261Pharmacogenomics in drug-induced cardiotoxicity: Current status and the futureMo-Yun Li0Mo-Yun Li1Li-Ming Peng2Li-Ming Peng3Li-Ming Peng4Xiao-Ping Chen5Xiao-Ping Chen6Xiao-Ping Chen7Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, ChinaDepartment of Cardiology, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, ChinaHunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDrug-induced cardiotoxicity (DICT) is an important concern of drug safety in both drug development and clinical application. The clinical manifestations of DICT include cardiomyopathy, arrhythmia, myocardial ischemia, heart failure, and a series of cardiac structural and functional changes. The occurrence of DICT has negative impacts on the life quality of the patients, brings additional social and economic burden. It is important to identify the potential factors and explore the mechanisms of DICT. Traditional cardiovascular risk factors can only partially explain the risk of DICT. Pharmacogenomic studies show accumulated evidence of genetics in DICT and suggest the potential to guide precision therapy to reduce risk of cardiotoxicity. The comprehensive application of technologies such as third-generation sequencing, human induced pluripotent stem (iPS) cells and genome editing has promoted the in-depth understanding of the functional role of susceptible genes in DICT. This paper reviewed drugs that cause DICT, the clinical manifestations and laboratory tests, as well as the related content of genetic variations associated with the risk of DICT, and further discussed the implication of new technologies in pharmacogenomics of DICT.https://www.frontiersin.org/articles/10.3389/fcvm.2022.966261/fulldrug-induced cardiotoxicitypharmacogenomicssingle nucleotide polymorphisms (SNPs)biomarkernew technologies in pharmacogenomics |
| spellingShingle | Mo-Yun Li Mo-Yun Li Li-Ming Peng Li-Ming Peng Li-Ming Peng Xiao-Ping Chen Xiao-Ping Chen Xiao-Ping Chen Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future Frontiers in Cardiovascular Medicine drug-induced cardiotoxicity pharmacogenomics single nucleotide polymorphisms (SNPs) biomarker new technologies in pharmacogenomics |
| title | Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future |
| title_full | Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future |
| title_fullStr | Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future |
| title_full_unstemmed | Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future |
| title_short | Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future |
| title_sort | pharmacogenomics in drug induced cardiotoxicity current status and the future |
| topic | drug-induced cardiotoxicity pharmacogenomics single nucleotide polymorphisms (SNPs) biomarker new technologies in pharmacogenomics |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.966261/full |
| work_keys_str_mv | AT moyunli pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT moyunli pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT limingpeng pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT limingpeng pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT limingpeng pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT xiaopingchen pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT xiaopingchen pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture AT xiaopingchen pharmacogenomicsindruginducedcardiotoxicitycurrentstatusandthefuture |